Want to see TSE:HEAL full AI Analyst Report?
HEAL Stock Chart & Stats
C$0.07
C$0.00(0.00%)
At close: 4:00 PM EDT
C$0.07
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.07 - C$0.14
Previous CloseN/A
Volume3.00K
Average Volume (3M)20.70K
Market Cap
C$4.69M
Enterprise ValueC$4.75M
Total Cash (Recent Filing)C$762.36K
Total Debt (Recent Filing)C$348.35K
Price to Earnings (P/E)―
Beta0.69
Next Earnings
Dec 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding62,506,542
10 Day Avg. Volume61,096
30 Day Avg. Volume20,698
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)3.29
Price to Sales (P/S)0.00
P/FCF Ratio-5.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved LeverageModest 2025 leverage provides greater financial flexibility than a heavily indebted structure. With debt low relative to equity, the company may face less interest pressure and retain more capacity to pursue operations or funding needs, although prior equity volatility remains relevant.
Asset-base RebuildingA rebuilding asset base is a constructive sign that the company has restored some balance-sheet resources compared with earlier periods. This can support future operations and financing discussions, giving the business a stronger foundation than its historically weaker asset position.
Reduced Cash BurnThe improvement in cash outflows from the 2021–2022 trough indicates that cash burn has moderated, even though it remains material. If maintained, this trend could extend the company’s financial runway and reduce the pace at which additional external capital is required.
Bears Say
No Recurring RevenueRevenue of zero across 2021–2025 indicates that the company has not established a dependable commercial revenue stream. Without recurring sales, operating funding remains difficult to generate internally, and the business lacks visible evidence of sustained product-market monetization.
Persistent Operating LossesPersistent negative EBIT and EBITDA show that core operations are not yet profitable, while the 2025 net loss confirms that earnings remain weak. This limits internally generated capital, makes performance dependent on future improvement, and weakens the durability of the business model.
Ongoing Cash DependenceNegative operating and free cash flow in every provided year means the company has not demonstrated cash self-sufficiency. Continued cash burn can consume available resources and leave future operations dependent on external funding, creating a persistent constraint on financial flexibility.
Restart Life Sciences News
HEAL FAQ
What was Restart Life Sciences’s price range in the past 12 months?
Restart Life Sciences lowest stock price was C$0.07 and its highest was C$0.14 in the past 12 months.
What is Restart Life Sciences’s market cap?
Restart Life Sciences’s market cap is C$4.69M.
When is Restart Life Sciences’s upcoming earnings report date?
Restart Life Sciences’s upcoming earnings report date is Dec 02, 2026 which is in 57 days.
How were Restart Life Sciences’s earnings last quarter?
Restart Life Sciences released its earnings results on Aug 27, 2026. The company reported -C$0.017 earnings per share for the quarter.
Is Restart Life Sciences overvalued?
According to Wall Street analysts Restart Life Sciences’s price is currently Overvalued.
Does Restart Life Sciences pay dividends?
Restart Life Sciences does not currently pay dividends.
What is Restart Life Sciences’s EPS estimate?
Restart Life Sciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Restart Life Sciences have?
Restart Life Sciences has 62,506,542 shares outstanding.
What happened to Restart Life Sciences’s price movement after its last earnings report?
Restart Life Sciences reported an EPS of -C$0.017 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Restart Life Sciences?
Currently, no hedge funds are holding shares in TSE:HEAL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Restart Life Sciences
Operating internationally through its various subsidiaries, Restart Life Sciences Corp. functions as a biotechnology firm. Its core endeavors include the creation of natural therapeutic remedies tailored for individuals with autism spectrum disorder, the development of health-promoting foods designed for comprehensive mind and body wellness, and the execution of a psilocybin clinical trial aimed at fragile X syndrome. Founded in 2004 and based in Vancouver, Canada, the company adopted its current name in November 2024, having previously been known as Nova Mentis Life Science Corp.